Patient P-01786

Synthetic patientNBL-101 · Day 94 · 65–74 · F · baseline S07Open companion preview

Therapy response

Declining

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

81%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S07
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 57 ME-01 recommended — Monitoring Escalation ME-01
Day 58 Patient accepted — Started ME-01 in the companion
Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Toxicity-11
GI instability-8
Treatment adherence-8
Inflammatory activity-7
Nutritional resilience+5

What helped?

Monitoring Escalation ME-01Day 57
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

87%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- WearableHRV 32 ms, trending down
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 47
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 28/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
Autonomic recovery ↑45
- WearableResting HR 80 bpm
- Wearable1,052 steps/day

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.1 · butyrate capacity 28/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 32 ms
Sleep: 7.2 h
Steps: 1,170
Resting HR: 81 bpm

Daily log: GI score 59, nutritional resilience 41, adherence 41.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01332	54%	S14	NP-02	improved	43
P-01554	53%	S05	GI-04	improved	47
P-01360	50%	S14	GI-04	improved	52
P-01429	50%	S09	GI-04	improved	45
P-01447	50%	S15	GI-04	improved	44
P-01834	50%	S14	NP-02	improved	44
P-01349	49%	S14	GI-04	improved	38
P-01409	49%	S14	SC-12	improved	41
P-01433	49%	S14	GI-04	improved	48
P-01810	49%	S05	NP-02	improved	43
P-01872	48%	S14	NP-02	improved	47
P-01496	47%	S14	SC-12	improved	46